Abstract: Microbial rennet from Rhizomucor pusillus which has been oxidized to increase its thermal lability has a normal pH of about 5.5 in aqueous solution. It has been discovered that the stability of such solutions can be increased by raising the pH to a level of from 6.0 to about 8.5.

Abstract: Disclosed is a method for increasing the milk clotting ability and reducing the thermal stability of microbial rennet from Rhizomucor pusillus. The method involves treating the rennet with a methionine oxidizing composition and the anhydride of a dicarboxylic organic acid.

Abstract: Disclosed is a method for increasing the milk clotting ability and reducing the thermal stability of microbial rennet from Rhizomucor pusillus. The method involves treating the rennet with a methionine oxidizing composition and the anhydride of a dicarboxylic organic acid.

Abstract: Disclosed are trans-2-substituted-amido-hexahydrobenzo[a]quinolizines represented by the formula: ##STR1## In the above formula, R.sup.1 and R.sup.2 are independently --H or --OCH.sub.3 or when taken together are ##STR2## R.sup.3 is --H or --CH.sub.3 and R.sup.4 is ##STR3## These compounds, and their pharmacologically acceptable, non-toxic, acid addition salts are useful as anti-hypertensive agents.

Abstract: Disclosed are novel 2-substituted anilino-hexahydrobenzo[a]quinolizines of the formula: ##STR1## wherein R and R' are independently H or --OCH.sub.3 and R" is ##STR2## These compounds, and their pharmacologically acceptable, non-toxic acid addition salts are useful as anti-hypertensive agents. Certain of the compounds disclosed herein elicit this effect without producing concomitant cardiac stimulation.

Abstract: Novel compounds having the structural formula ##STR1## wherein R.sub.1 is hydrogen, i-propyl, phenyl or a substituted phenyl having the structure ##STR2## wherein R.sub.2 is halogen, methoxy, lower alkyl, nitro, trifluoromethyl, acetamido, or sulfonamido and their acid addition salts, are useful for treatment of cardiovascular disorders such as cardiac arrhythmia, hypertension, and angina pectoris. Methods for preparation and use of these compounds are described.

Abstract: Derivatives of 5-(indol-3-yl)hydantoin characterized by the generic structural formula, ##STR1## and their pharmacologically compatible salts are useful in the treatment of cardiac arrythmias in individuals for whom such therapy is indicated. In the preceding structural formula, A is a hydrogen atom, a halogeno, alkyl, hydroxyl, or an alkoxyl radical; n is 0 or 1; R is a hydrogen atom or a phenyl group; X is a methylene, ethylene, trimethylene, or 2-hydroxytrimethylene radical; and Z is a monoalkylamino radical containing 1-4 carbon atoms, a dialkylamino radical containing 2-8 carbon atoms, a morpholino, piperid-1-yl, 4-phenyl-piperid-1-yl, or a 4-hydroxy-4-phenyl-piperid-1-yl radical.